Prognostic factors for progression-free and overall survival in malignant pleural mesothelioma
| Autor: | Jordi Guzmán-Casta, Rodrigo Riera-Sala, Luis Manuel Martínez-Barrera, Jerónimo Rafael Rodríguez-Cid, Carla Paola Sánchez-Ríos, Diana Bonilla-Molina, Sonia Carrasco-CaraChards, Erika Sagrario Peña-Mirabal, Jorge Arturo Alatorre-Alexander, Jorge Guzmán-Huesca, José Fabián Martínez-Herrera |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology Adult Male medicine.medical_specialty Adolescent medicine.medical_treatment overall survival Malignant pleural mesothelioma lcsh:RC254-282 03 medical and health sciences Young Adult 0302 clinical medicine Internal medicine medicine Humans Progression-free survival Mesothelioma Risk factor Stage (cooking) Retrospective Studies business.industry Mesothelioma Malignant Cancer prognostic factors Retrospective cohort study progression‐free survival General Medicine Original Articles lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Prognosis Progression-Free Survival Radiation therapy 030104 developmental biology 030220 oncology & carcinogenesis Concomitant Female Original Article business |
| Zdroj: | Thoracic Cancer Thoracic Cancer, Vol 12, Iss 7, Pp 1014-1022 (2021) |
| ISSN: | 1759-7714 |
| Popis: | Background Malignant pleural mesothelioma is an infrequent neoplasia with a poor prognosis and the majority of patients already have advanced disease at the time of presentation. Exposure to asbestos is the most important risk factor for malignant pleural mesothelioma. Mesothelioma is a neoplasia with a long preclinical stage that can span from 15 to 40 years. Methods This was a descriptive, observational, retrospective study of 136 patients with a confirmed diagnosis of mesothelioma, which compared histological subtypes, immunohistochemical biomarkers, concomitant chronic degenerative diseases, tobacco use, age at the time of diagnosis, clinical stage and chemotherapy agents used or other treatments such as radiotherapy and surgery to identify all the factors that impact in the prognosis of overall survival (OS) and progression‐free survival (PFS). Results A total of 136 patients were included in the study. In the total study population, 84 patients were male (61.8%) and 52 were female (38.2%). Median PFS was nine months (95% confidence interval [CI]: 8.4–9.5 months) and median OS was 12 months (95% CI: 11.3–12.6). The results indicated that the most determining prognostic factors for OS and PFS were cell differentiation measured by immunohistochemical biomarkers, the treatment chosen, and that RECIST was the most significant in the evaluation of patient response to treatment. Conclusions Malignant pleural mesothelioma is a cancer with a poor prognosis usually diagnosed at an advanced stage of disease. Our study revealed that the prognostic factors for OS and PS were cell differentiation, the treatment chosen and RECIST. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text